Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 01:46, 17 March 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid) per Chem/Drugbox validation (report errors or bugs)← Previous edit		Latest revision as of 21:53, 16 September 2024 edit undo76.174.0.57 (talk) Cat.
(206 intermediate revisions by more than 100 users not shown)
Line 1:		Line 1:
			{{Short description|Chemical compound}}
	{{drugbox
			{{pp-pc}}
	| verifiedrevid = 416055650
			{{Use dmy dates|date=November 2017}}
	| IUPAC_name = ''1--<BR>4-piperidinyl]-1,3-dihydro-<BR>2''H''-benzimidazole-2-one''
			{{Use American English|date=November 2017}}
	| image = Pimozide.svg
	| width = 220
	| CASNo_Ref = {{cascite|correct|CAS}}
	| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
	| ChemSpiderID = 15520
	| UNII_Ref = {{fdacite|correct|FDA}}
	| UNII = 1HIZ4DL86F
	| InChI = 1/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
	| InChIKey = YVUQSNJEYSNKRX-UHFFFAOYAD
	| smiles = Fc1ccc(cc1)C(c2ccc(F)cc2)CCCN5CCC(N4c3ccccc3NC4=O)CC5
	| ChEMBL_Ref = {{ebicite|correct|EBI}}
	| ChEMBL = 1423
	| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChI = 1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
	| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChIKey = YVUQSNJEYSNKRX-UHFFFAOYSA-N
	| CAS_number = 2062-78-4
	| ATC_prefix = N05
	| ATC_suffix = AG02
	| PubChem = 16362
	| IUPHAR_ligand = 90
	| DrugBank = APRD00218
	| KEGG_Ref = {{keggcite|correct|kegg}}
	| KEGG = D00560
	| C=28 | H=29 | F=2 | N=3 | O=1
	| molecular_weight = 461.56
	| bioavailability = at least 40 to 50%
	| metabolism = hepatic, by cytochrome P450, isoenzymes 3A, and 1A2; metabolites are inactive
	| elimination_half-life = 2 to 3 days (average in one study 55 hours)
	| excretion = urine, and to a lesser extent in feces
	| pregnancy_category = Teratogenic data in rats exist : drug should only be used when the benefit clearly exceeds the potential harm to the unborn
	| legal_status = Rx-only, not a controlled narcotic
	| routes_of_administration = oral only
	}}
			{{infobox drug
	'''Pimozide''' ('''Orap''') is an ] ] of the ] class. It was discovered at ] in 1963. It has a high potency compared to ] (ratio 50-70:1). On a weight basis it is even more potent than ]. It also has special neurologic indications for ] and resistant ]. The side effects include ], ], and, more rarely, ] and ].
			| Watchedfields = changed
			| verifiedrevid = 464206733
			| IUPAC_name = 1--4-piperidinyl]-1,3-dihydro-2''H''-benzimidazole-2-one
			| image = Pimozide.svg
			| width = 200
			| image2 = Pimozide-based-on-xtal-3D-bs-17.png
			<!--Clinical data-->
	== Uses ==
			| tradename = Orap
	Pimozide is used in its oral preparation in ] and chronic ] (on-label indications in Europe only), Tourette syndrome and resistant ] (Europe, USA and Canada). In Germany the 1&nbsp;mg tablet is indicated for the treatment of some forms of reactive depression.
			| Drugs.com = {{drugs.com|monograph|pimozide}}
			| MedlinePlus = a686018
			| licence_US = Pimozide
			| pregnancy_AU = B1
			| pregnancy_US = C
			| legal_AU = S4
			| legal_BR = C1
			| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=] |language=pt-BR |publication-date=2023-04-04}}</ref>
			| legal_US = Rx-only
			| routes_of_administration = Oral
			| class = ]
			<!--Pharmacokinetic data-->
	== Off-label use ==
			| bioavailability = 40-50%
			| metabolism = ], ] and ]
			| elimination_half-life = 55 hours (adults), 66 hours (children)
			| excretion = Urine
			<!--Identifiers-->
	Pimozide has been used in the treatment of ].<ref>Munro, A. (1999) ''Delusional disorder''. Cambridge: Cambridge University Press. ISBN 0-521-58180-X</ref>
			| CAS_number_Ref = {{cascite|correct|??}}
			| CAS_number = 2062-78-4
			| ATC_prefix = N05
			| ATC_suffix = AG02
			| PubChem = 16362
			| IUPHAR_ligand = 90
			| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
			| DrugBank = DB01100
			| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
			| ChemSpiderID = 15520
			| UNII_Ref = {{fdacite|correct|FDA}}
			| UNII = 1HIZ4DL86F
			| KEGG_Ref = {{keggcite|correct|kegg}}
			| KEGG = D00560
			| ChEBI_Ref = {{ebicite|correct|EBI}}
			| ChEBI = 8212
			| ChEMBL_Ref = {{ebicite|correct|EBI}}
			| ChEMBL = 1423
			<!--Chemical data-->
	It has been used for ].<ref name="pmid12639456">{{cite journal |author=van Vloten WA |title=Pimozide: use in dermatology |journal=Dermatol. Online J. |volume=9 |issue=2 |pages=3 |year=2003 |month=March |pmid=12639456 |doi= |url=http://dermatology.cdlib.org/92/reviews/pimozide/vanvloten.html }}</ref>
			|C=28 |H=29 |F=2 |N=3 |O=1
			| smiles = Fc1ccc(cc1)C(c2ccc(F)cc2)CCCN5CCC(N4c3ccccc3NC4=O)CC5
			| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
			| StdInChI = 1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
			| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
			| StdInChIKey = YVUQSNJEYSNKRX-UHFFFAOYSA-N
			}}
			'''Pimozide''' (sold under the brand name '''Orap''') is a neuroleptic ] of the ] class. It was discovered at ] in 1963. It has a high potency compared to ] (ratio 50-70:1). On a weight basis it is even more potent than ]. It also has special indication for ] and resistant ].
	Use as a ] inhibitor has been described.<ref name="pmid19015342">{{cite journal |author=Lieberman LA, Higgins DE |title=A small-molecule screen identifies the antipsychotic drug pimozide as an inhibitor of Listeria monocytogenes infection |journal=Antimicrob. Agents Chemother. |volume=53 |issue=2 |pages=756–64 |year=2009 |month=February |pmid=19015342 |pmc=2630664 |doi=10.1128/AAC.00607-08 |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=19015342}}</ref>
	== Chemistry ==		== Medical uses ==
			Pimozide is used for Tourette syndrome,<ref name="Pimozide_1985"/> and resistant ] (Europe, United States, and Canada) and in Europe for ], chronic ], ], and ].<ref>{{cite book | vauthors = Munro A | date = 1999 | title = Delusional disorder | location = Cambridge | publisher = Cambridge University Press | isbn = 0-521-58180-X }}</ref>
	Pimozide is a diphenylbutylpiperidine derivative.
	== Pharmacology ==		== Efficacy ==
	=== Pharmacokinetics ===
			A 2013 ] compared pimozide with other antipsychotics for schizophrenia or related psychoses: Pimozide versus any other antipsychotic<ref name=Mot2013>{{cite journal | vauthors = Mothi M, Sampson S | title = Pimozide for schizophrenia or related psychoses | journal = The Cochrane Database of Systematic Reviews | volume = 11 | issue = 11 | pages = CD001949 | date = November 2013 | pmid = 24194433 | doi = 10.1002/14651858.CD001949.pub3 | url = http://www.cochrane.org/CD001949/SCHIZ_pimozide-for-schizophrenia-or-related-psychoses | url-status = live | df = dmy-all | archive-url = https://web.archive.org/web/20171127123319/http://www.cochrane.org/CD001949/SCHIZ_pimozide-for-schizophrenia-or-related-psychoses | archive-date = 27 November 2017 }}</ref>
	Plasma levels of pimozide can vary widely between patients, and in insufficient response ] may be required to ascertain that the patient is developing adequate plasma levels before withdrawing the drug and attempting other antipsychotics.
			In one case a series of 33 patients with delusional parasitosis (median age, 60 years), pimozide was prescribed for 24 patients, 18 of whom took the drug. The dose ranged from 1 to 5&nbsp;mg daily. No information regarding initial dosing was specified, although the dose was continued for 6 weeks prior to tapering. Of those patients receiving pimozide, 61% (11/18) experienced improvement in or full remission of symptoms. The use of pimozide for the treatment of delusional parasitosis is based primarily on data from case series/reports that demonstrate some efficacy in the majority of patients. Currently, ]s such as ] or ] are used as first line treatment. However, patients who experience negative side-effects with the first line medications are typically given pimozide.<ref>{{cite journal | vauthors = Generali JA, Cada DJ | title = Pimozide: parasitosis (delusional) | journal = Hospital Pharmacy | volume = 49 | issue = 2 | pages = 134–135 | date = February 2014 | pmid = 24623867 | pmc = 3940679 | doi = 10.1310/hpj4902-134 }}</ref><ref>{{cite journal | vauthors = Meehan WJ, Badreshia S, Mackley CL | title = Successful treatment of delusions of parasitosis with olanzapine | journal = Archives of Dermatology | volume = 142 | issue = 3 | pages = 352–355 | date = March 2006 | pmid = 16549712 | doi = 10.1001/archderm.142.3.352 | doi-access = }}</ref>
	=== Pharmacodynamics ===
			== Contraindications ==
	Pimozide blocks the following postsynaptic receptors according to Bezchlinyk-Butler and Jeffries:
			It is contraindicated in individuals with either acquired, congenital or a family history of QT interval prolongation.<ref name = EMC /> Its use is advised against in individuals with people with either a personal or a family history of arrhythmias or ].<ref name = EMC /> Likewise its use is also advised against in individuals with uncorrected ] and ] or clinical significant cardiac disorders (e.g. a recent ] or ].<ref name =EMC /> It is also contraindicated in individuals being cotreated with ] (SSRI) or in those with a known hypersensitivity to pimozide or other diphenylbutyl-piperidine derivatives.<ref name = EMC /> Likewise its use is contraindicated in individuals receiving treatment with ], ], or ] inhibitors.<ref name = EMC />
	* Extremely strong: ]
	* Strong: ], ], ]
	* Moderate: ], ], ]
	* Weak: ], ]
	* Extremely weak: ]
	Pimozide also inhibits moderately the ] (DAT), accounting for the stimulant properties of the drug. The inhibition of dopamine-reuptake may also explain the synergistic effects of pimozide in the treatment of ADHD when given together with a stimulant.
	== Contraindications and precautions ==
	* Contraindicated in patients taking citalopram ](Celexa) and escitalopram ] (Lexapro) due to prolongation of the QTc interval, as per the FDA.
	* Patients with prominent agitation or anxiety
	* Depressed patients
	* Severe intoxication with alcohol, opiates, and psychoactive drugs (e.g. antidepressants, benzodiazepines)
	* Preexisting ]
	* Comedication with ], ] and vetoconazol (see below under interactions)
	* Caution: Anticonvulsive treatment in epileptic patients should not be interrupted. Pimozide may in principle lower the seizure-threshold.
	* Caution: Patients under 18 yrs. of age. Side effects may be particularly frequent and severe. Treatment should be started with low initial dose and the dose increased very slowly.
	== Side effects ==		== Side effects ==
			Very common (>10% frequency) side effects include:<ref name = MSR /><ref name = EMC /><ref name = MD /><ref name = DM />
	{{see|Typical antipsychotic}}
			* ]
	Pimozide can have severe, potentially fatal side effects. As with other ] antagonists pimozide can cause various ]s, including ] and ]. The frequency of extrapyramidal side effects is quite high. ] may also occur.
			* Constipation
			* Dizziness
			* Dry mouth
			* ]
			* ]
			* ]
			* Speech disorder
			== Overdose ==
	In particular, pimozide is known for causing the unpleasant extrapyramidal side effect ] (commonly referred to as "restless pacing") in a large percentage of those who take it. This "restlessness" can sometimes be treated with ] drugs (mainly ]), ] or ]s, particularly ] (Klonopin). Unfortunately, in many cases this side effect can be so intense that even large doses of these drugs are unable to counter it, and often is so extreme that self-destructive behaviour, including attempting ], may occur.
			Pimozide overdose presents with severe ], ], ], QT interval prolongation and ventricular arrhythmias including ].<ref name = EMC /> Gastric lavage, establishment of a patent airway and, if necessary, mechanically assisted respiration is the recommended treatment for pimozide overdose.<ref name = EMC /> Cardiac monitoring should be continued for at least 4 days due to the long half-life of pimozide.<ref name = EMC />
	Pimozide has no significant sedative properties, but behaves in some patients as a mild stimulant. If the drug is given shortly before bedtime, ] may result. Excitement, agitation, irritability, tension, anxiety, and nightmares have all been seen.
			== Pharmacology ==
	The drug can also cause depression in quite a number of patients, severe enough to result in suicide.
			Pimozide acts as an ] of the ], ], and ] and the ]. It is also a ] ].
	Pimozide has few but nonetheless existing anticholinerg side effects (e.g. dry mouth, obstipation, urinary hesitancy), rarely of clinical importance.
			Similarly to other typical antipsychotics pimozide has a high affinity for the ] and this likely results in its sexual (due to ]) and extrapyramidal side effects as well as its therapeutic efficacy against the positive symptoms of ].<ref name="Maudsley">{{cite book |isbn = 978-0-470-97948-8 |title = The Maudsley prescribing guidelines in psychiatry | vauthors = Taylor D, Paton C, Shitij K |year = 2012 |publisher = Wiley-Blackwell |location = West Sussex }}</ref>
	Pimozide may rarely cause seizures of the grand-mal-type. Patients with epilepsia should be counselled to maintain anticonvulsive therapy.
			{| class="wikitable sortable"
	Particularly disturbing is a relatively high incidence of the ], which may lead to ], ] and death via ].
			|+ <big>Binding profile</big><ref group = Note>A lower K<sub>i</sub> value indicates a stronger binding</ref>
			! Protein !! K<sub>i</sub> (nM)<ref>{{cite web |title = PDSP K<sub>i</sub> Database |work = Psychoactive Drug Screening Program (PDSP) | vauthors = Roth BL, Driscol J |author1-link=Bryan Roth|url = http://pdsp.med.unc.edu/pdsp.php |publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health |access-date = 4 December 2013 |date = 12 January 2011 |url-status = dead |archive-url = https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archive-date = 8 November 2013 |df = dmy-all }}</ref> !! Notes
			|-
			| ] || 650 ||
			|-
			| ] || 48.4 || This receptor is believed to be responsible for the atypicality of other antipsychotics like ], ] and ]. Pimozide's affinity towards this receptor is low compared to its affinity for the D<sub>2</sub> receptor and hence this receptor unlikely contributes to its effects to any meaningful extent.
			|-
			| ] || 2,112 ||
			|-
			| ] || 71 ||
			|-
			| ] || 0.5 || Relatively high affinity for this receptor may explain its supposed antidepressant-like effects in animal models of depression.<ref>{{cite journal | vauthors = Mahesh R, Pandey DK, Bhatt S, Gautam BK |title = Anti-depressant like Effect of Pimozide in Acute and Chronic Animal Models of Depression |journal = Indian Journal of Pharmaceutical Education and Research |volume = 45 |issue = 1 |pages = 46–53 |date = January–March 2011 }}</ref>
			|-
			| ] || 197.7 || Low affinity towards this receptor may explain why pimozide has a lower liability for producing orthostatic hypotension.<ref name = Maudsley />
			|-
			| ] || 1,593 ||
			|-
			| ] || 821 ||
			|-
			| ] || 376.5 ||
			|-
			| ] || 1,955 || This receptor is believed to be responsible for the interference with glucose ] seen with some of the ] such as ] and ].<ref name="GG">{{cite book |isbn = 978-0-07-162442-8 |title = Goodman and Gilman's The Pharmacological Basis of Therapeutics |edition = 12th | vauthors = Brunton L, Chabner B, Knollman B |year = 2010 |publisher = McGraw-Hill Professional |location = New York |title-link = Goodman and Gilman's The Pharmacological Basis of Therapeutics }}</ref> Pimozide's low affinity for this receptor likely contributes to the comparatively mild effects on glucose homeostasis.
			|-
			| ] || >10,000 ||
			|-
			| ] || 0.33 || Likely the receptor responsible for the therapeutic effects against the positive symptoms of schizophrenia of antipsychotics like pimozide as well as the prolactin-elevating and extrapyramidal side effect-generating effects of typical antipsychotics like pimozide.<ref name = GG />
			|-
			| ] || 0.25 ||
			|-
			| ] || 1.8 ||
			|-
			| ] || 18 || May be responsible for pimozide's high liability for prolonging the QT interval.<ref name = GG />
			|-
			| ] || 692 || Likely responsible for why pimozide tends to produce so little sedation.<ref name =" GG" />
			|-
			| ] || 508 ||
			|}
			{| class="wikitable" align="left"
	There is also specific information of carcinogenity both in animals and humans. The carcinogenity in animals has been proven and the carcinogenity in man is strongly suspected (breast cancer and probably liver tumors).
			|+ <big>Pharmacokinetic data</big><ref name=MSR>{{cite web |title = Oral (pimozide) dosing, indications, interactions, adverse effects, and more |work = Medscape Reference |publisher = WebMD |access-date = 4 December 2013 |url = http://reference.medscape.com/drug/orap-pimozide-342982#showall |url-status = live |archive-url = https://web.archive.org/web/20131204215602/http://reference.medscape.com/drug/orap-pimozide-342982#showall |archive-date = 4 December 2013 |df = dmy-all }}</ref><ref name=EMC>{{cite web |title = Oral 4 mg tablets. - Summary of Product Characteristics |work = electronic Medicines Compendium |publisher = Janssen-Cilag Ltd |date = 2 April 2013 |access-date = 4 December 2013 |url = http://www.medicines.org.uk/emc/medicine/6753/SPC/Orap+4+mg+tablets./ |url-status = dead |archive-url = https://web.archive.org/web/20160303230421/http://www.medicines.org.uk/emc/medicine/6753/SPC/Orap+4+mg+tablets./ |archive-date = 3 March 2016 }}</ref><ref name = MD>{{cite book |title = Pimozide | vauthors = Brayfield A |work = Martindale: The Complete Drug Reference |publisher = Pharmaceutical Press |location = London, UK |url = https://www.medicinescomplete.com/mc/martindale/current/7087-n.htm |access-date = 4 December 2013 |date = 12 February 2013 }}</ref><ref name=DM>{{cite web |title = ORAP (pimozide) tablet |work = DailyMed |publisher = Teva Select Brands |date = July 2012 |url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd9729c3-545f-4d34-9bc7-72b61e028fc4 |access-date = 4 December 2013 |url-status = live |archive-url = https://web.archive.org/web/20130703154327/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd9729c3-545f-4d34-9bc7-72b61e028fc4 |archive-date = 3 July 2013 |df = dmy-all }}</ref>
			! Pharmacokinetic parameter !! Value
			|-
			| Time to peak plasma concentration (T<sub>max</sub>) || 6-8 hr
			|-
			| Peak plasma concentration (C<sub>max</sub>) || 4-19&nbsp;ng/mL
			|-
			| Elimination half-life (t<sub>1/2</sub>) || 55 hours (adults), 66 hours (children)
			|-
			| Metabolising enzymes || ], ] and ]
			|-
			| Excretion pathways || Urine
			|}
			{{clear}}
			== History ==
	Because of these serious side effects, Pimozide should only be used after the patient has received full information about the drug and agrees to treatment with it despite the risks (fully ]).
			In 1985 pimozide was approved by the FDA for marketing as an ] for the treatment of Tourette's syndrome.<ref name="Pimozide_1985">{{cite journal | vauthors = Colvin CL, Tankanow RM | title = Pimozide: use in Tourette's syndrome | journal = Drug Intelligence & Clinical Pharmacy | volume = 19 | issue = 6 | pages = 421–424 | date = June 1985 | pmid = 3891283 | doi = 10.1177/106002808501900602 | s2cid = 19179304 }}</ref>
	Given to a non-psychotic patient, Pimozide can result in severe disabilities, both mental and physical. Loss of ability to lead a conversation is a common side effect. Due to that specific side effect, patients who have been wrongly given Pimozide cannot explain their need to stop taking the medication. Pimozide should be prescribed only after a complete medical examination and consensus between the patient and doctor.
			== See also ==
	There have been reported cases of irreversible ] in healthy patients treated with Pimozide.
			{{Portal|Medicine}}
	== Interactions ==
			* ]
	* Central Depressants: Action of the other drug may be increased.
			* ]
	* Drugs competing for the same cytochrome subenzymes: Risk of mutual and uncontrollable increased action. ], ], ] and ] all lead to increased pimozide plasma levels and to a higher incidence of (potentially serious) side effects of pimozide.
			* ]
	* Grapefruit juice: Elimination of Pimozide is inhibited. Avoid drinking grapefruit juice during treatment with Pimozide.
			* ]
	== Dosage ==		== Notes ==
			{{reflist|group=Note}}
	Due to its long halflife pimozide is usually given once a day (preferably in the morning, because pimozide may have a rather stimulating effect).
			== References ==
	Recommended dose ranges are as follows:
	* Acute psychotic disorders: usually 2 to 12&nbsp;mg daily starting with low doses, then slowly increasing. More than 20&nbsp;mg daily should be avoided, because the benefit-risk ratio is unclear
	* Chronic psychotic disorders: for maintenance of acute results 6&nbsp;mg daily is the usual dose
	* Tics: 1 to 16&nbsp;mg daily in slowly increasing doses
	* Reactive Depression: 1 to 2&nbsp;mg daily
	* ADHD: not clearly established, start with very small doses (e.g. 0.5 to 1.0&nbsp;mg) and increase slowly according to the clinical reaction and the side effects encountered.
			{{Reflist}}
	== Animal toxicity and human overdose ==
	The precise lethal dose in humans is unknown. The oral LD50 is 228&nbsp;mg/kg in mice, 5120&nbsp;mg/kg in rats, 188&nbsp;mg/kg in guinea pigs, and 40&nbsp;mg/kg in dogs.
	Generally human overdoses show exaggerations of the pharmacologic effect of Pimozide. These are : ECG-abnormalities, severe extrapyramidal reactions, hypotension, and comatose state with respiratory depression.
	Treatment is largely symptomatic. No specific antidote exists. Induction of emesis, gastric lavage and the repeated application of activated charcoal can all be helpful. Monitor and stabilize, if necessary, the vital functions. Hospitialization and/or admittance to intensive care treatment is in most cases necessary. Due to the long halflife of Pimozide, the symptoms of overdose may last for several days.
	==Synthesis==
	]
	]
	]
	Janssen, P. A. J.; Soudijn,W.; VanWijngaarden, I.; Dreese A.; Arzneimittel-Forsch. 1968,
	18, 282.
	*P. Meisel, H.-J. Heidrich, H.-J. Hansch, E. Kretzschman, S. Henker, G. Laban, Ger. (Dem.) {{Cite patent|DD|243284}} (1987).
	*P.A.J. Janssen, {{US Patent|3196157}} (1965).
	*P. Janssen, {{Cite patent|DE|1470124}} (1963).
	(See also: ])
	== References ==
	{{Reflist|2}}
	== External links ==		== External links ==
	* (A medical white paper on its use)
	* (patient information)
	{{Antipsychotics}}		{{Antipsychotics}}
			{{Navboxes
	{{Cholinergics}}
			| title = ]
	{{Dopaminergics}}
			| titlestyle = background:#ccccff
	{{Histaminergics}}
			| list1 =
	{{Serotonergics}}
			{{Dopamine receptor modulators}}
			{{Ion channel modulators}}
			{{Serotonin receptor modulators}}
			{{Sigma receptor modulators}}
			}}
			{{authority control}}
	]		]
	]		]
	]		]
			]
			]
			]
			]
			]
			]
			]
	]		]
			]
			]
	]
			]
	]
			]
	]
	]
	]
	]